Potent Inhibitor of Human Trypsins from the Aeruginosin Family of Natural Products
Publiceringsår
2021
Upphovspersoner
Ahmed, Muhammad N.; Wahlsten, Matti; Jokela, Jouni; Nees, Matthias; Stenman, Ulf-Håkan; Alvarenga, Danillo O.; Strandin, Tomas; Sivonen, Kaarina; Poso, Antti; Permi, Perttu; Metsä-Ketelä, Mikko; Koistinen, Hannu; Fewer, David P.
Abstrakt
Serine proteases regulate many physiological processes and play a key role in a variety of cancers. Aeruginosins are a family of natural products produced by cyanobacteria that exhibit pronounced structural diversity and potent serine protease inhibition. Here, we sequenced the complete genome of Nodularia sphaerocarpa UHCC 0038 and identified the 43.7 kb suomilide biosynthetic gene cluster. Bioinformatic analysis demonstrated that suomilide belongs to the aeruginosin family of natural products. We identified 103 complete aeruginosin biosynthetic gene clusters from 12 cyanobacterial genera and showed that they encode an unexpected chemical diversity. Surprisingly, purified suomilide inhibited human trypsin-2 and -3, with IC50 values of 4.7 and 11.5 nM, respectively, while trypsin-1 was inhibited with an IC50 of 104 nM. Molecular dynamics simulations suggested that suomilide has a long residence time when bound to trypsins. This was confirmed experimentally for trypsin-1 and -3 (residence times of 1.5 and 57 min, respectively). Suomilide also inhibited the invasion of aggressive and metastatic PC-3M prostate cancer cells without affecting cell proliferation. The potent inhibition of trypsin-3, together with a long residence time and the ability to inhibit prostate cancer cell invasion, makes suomilide an attractive drug lead for targeting cancers that overexpress trypsin-3. These results substantially broaden the genetic and chemical diversity of the aeruginosin family and suggest that aeruginosins may be a source of selective inhibitors of human serine proteases.
Visa merOrganisationer och upphovspersoner
Östra Finlands universitet
Poso Antti
Helsingfors universitet
Poso Antti
Alvarenga Danillo O.
Fewer David P.
Koistinen Hannu
Jokela Jouni
Sivonen Kaarina
Wahlsten Matti
Ahmed Muhammad N.
Permi Perttu
Strandin Tomas
Stenman Ulf Håkan
Helsingfors universitetssjukhus
Poso Antti
Alvarenga Danillo O.
Fewer David P.
Koistinen Hannu
Jokela Jouni
Sivonen Kaarina
Wahlsten Matti
Ahmed Muhammad N.
Permi Perttu
Strandin Tomas
Stenman Ulf Håkan
Publikationstyp
Publikationsform
Artikel
Rapport
Nej
Moderpublikationens typ
Tidning
Artikelstyp
En originalartikelMålgrupp
VetenskapligKollegialt utvärderad
Kollegialt utvärderadUKM:s publikationstyp
A1 Originalartikel i en vetenskaplig tidskriftPublikationskanalens uppgifter
Journal/Serie
Moderpublikationens namn
Volym
16
Nummer
11
Sidor
2537-2546
ISSN
Publikationsforum
Publikationsforumsnivå
2
Öppen tillgång
Öppen tillgänglighet i förläggarens tjänst
Ja
Öppen tillgång till publikationskanalen
Delvis öppen publikationskanal
Parallellsparad
Ja
Övriga uppgifter
Vetenskapsområden
Kemi; Farmaci; Biokemi, cell- och molekylärbiologi; Biomedicinska vetenskaper; Cancersjukdomar
Identifierade tema
[object Object]
Publiceringsland
Förenta staterna (USA)
Förlagets internationalitet
Internationell
Språk
engelska
Internationell sampublikation
Ja
Sampublikation med ett företag
Nej
DOI
10.1021/acschembio.1c00611
Publikationen ingår i undervisnings- och kulturministeriets datainsamling
Ja